Socio-behavioral and geographic correlates of prevalent hepatitis C virus infection among young injection drug users in metropolitan Baltimore and Chicago

Drug and Alcohol Dependence

Volumn 111, Issue 1-2, 2010, Pages 136-145

  Boodram, Basmattee ^a   Golub, Elizabeth T ^b   Ouellet, Lawrence J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CIDUS III; City; Geographic; Hepatitis C; Injection drug user; Prevalence

Indexed keywords

COCAINE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; SOCIAL BEHAVIOR; SYRINGE; UNITED STATES; URBAN AREA;

ADOLESCENT; ADULT; BALTIMORE; CHICAGO; DRUG USERS; FEMALE; HEPATITIS C; HUMANS; LOGISTIC MODELS; MALE; NEEDLE SHARING; NEEDLE-EXCHANGE PROGRAMS; ODDS RATIO; PREVALENCE; RISK FACTORS; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77956189656     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.04.003     Document Type: Article

References (51)

1. Aceijas C., Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int. J. Drug Policy 2007, 18:352-358.
2. Alter M.J. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 2007, 13:2436-2441.
3. Alter, M.J., Kuhnert, W.L., Finelli, L., 2003. Guidelines for Laboratory Testing and Result Reporting of Antibody to Hepatitis C Virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 52, pp. 1-13, 15, quiz CE11-14.
4. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 2006, 144:705-714.
5. Ashton M. Hepatitis C and needle exchange. Pt. II. Drug Alcohol Findings 2003, 9:24-32.
6. Ashton M. Hepatitis C and needle exchange. Pt. III. Drug Alcohol Findings 2003, 10:22-25.
7. Bergk A., Berg T., Neumann U.P. Risk factors for the acquisition of hepatitis C. Minerva Gastroenterol. Dietol. 2005, 51:7-14.
8. Brewer D.D., Hagan H., Sullivan D.G., Muth S.Q., Hough E.S., Feuerborn N.A., Gretch D.R. Social structural and behavioral underpinnings of hyperendemic hepatitis C virus transmission in drug injectors. J. Infect. Dis. 2006, 194:764-772.
9. Broz D., Ouellet L.J. Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug Alcohol Depend. 2008, 94:221-233.
10. Cao W., Treloar C. Comparison of needle and syringe programme attendees and non-attendees from a high drug-using area in Sydney, New South Wales. Drug Alcohol Rev. 2006, 25:439-444.
11. Centers for Disease Control and Prevention, 1998. Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-related Chronic Disease MMWR. 47(RR-19), pp. 1-39.
12. Crofts N., Hopper J.L., Bowden D.S., Breschkin A.M., Milner R., Locarnini S.A. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med. J. Aust. 1993, 159:237-241.
13. Des Jarlais D.C., Perlis T., Arasteh K., Torian L.V., Hagan H., Beatrice S., Smith L., Wethers J., Milliken J., Mildvan D., Yancovitz S., Friedman S.R. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 2005, 19(Suppl. 3):S20-S25.
14. Evans J.L., Hahn J.A., Page-Shafer K., Lum P.J., Stein E.S., Davidson P.J., Moss A.R. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J. Urban Health 2003, 80:137-146.
15. Falster K., Kaldor J.M., Maher L. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004. J. Urban Health 2009, 86:106-118.
16. Fisher D.G., Reynolds G.L., Jaffe A., Perez M.J. Hepatitis and human immunodeficiency virus co-infection among injection drug users in Los Angeles County, California. J. Addict. Dis. 2006, 25:25-32.
17. Garfein R.S., Swartzendruber A., Ouellet L.J., Kapadia F., Hudson S.M., Thiede H., Strathdee S.A., Williams I.T., Bailey S.L., Hagan H., Golub E.T., Kerndt P., Hanson D.L., Latka M.H. Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug Alcohol Depend. 2007, 91(Suppl. 1):S4-S17.
18. Garfein R.S., Vlahov D., Galai N., Doherty M.C., Nelson K.E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am. J. Public Health 1996, 86:655-661.
19. Gibson D.R., Flynn N.M., Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 2001, 15:1329-1341.
20. Global Burden of Hepatitis C Work Group The global burden of hepatitis C. J. Clin. Pharm. 2004, 204:20-29.
21. Hagan H., Des Jarlais D.C., Stern R., Lelutiu-Weinberger C., Scheinmann R., Strauss S., Flom P.L. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int. J. Drug Policy 2007, 18:341-351.
22. Hagan H., McGough J.P., Thiede H., Hopkins S.G., Weiss N.S., Alexander E.R. Volunteer bias in nonrandomized evaluations of the efficacy of needle-exchange programs. J. Urban Health 2000, 77:103-112.
23. Hagan H., Thiede H., Des Jarlais D.C. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 2004, 15:543-549.
24. Hagan H., Weiss N., Thiede H., Hopkins S., McGough J.P., Alexander E.R. Reply to " Invited commentary: needle exchange-no help for hepatitis?" by Moss and Hahn. Am. J. Epidemiol. 1999, 149:217-218.
25. Hahn J.A., Page-Shafer K., Lum P.J., Ochoa K., Moss A.R. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001, 34:180-187.
26. Hahn J.A., Vranizan K.M., Moss A.R. Who uses needle exchange? A study of injection drug users in treatment in San Francisco, 1989-1990. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1997, 15:157-164.
27. Heckathorn D. Respondent-driven sampling: a new approach to the study of hidden populations. Social Problems 1997, 44:174-199.
28. Hickman M., Hope V., Brady T., Madden P., Jones S., Honor S., Holloway G., Ncube F., Parry J. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J. Viral Hepat. 2007, 14:645-652.
29. Holtzman D., Barry V., Ouellet L.J., Des Jarlais D.C., Vlahov D., Golub E.T., Hudson S.M., Garfein R.S. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Prev. Med. 2009, 49:68-73.
30. Junge B., Valente T., Latkin C., Riley E., Vlahov D. Syringe exchange not associated with social network formation: results from Baltimore. AIDS 2000, 14:423-426.
31. Kiyosawa K., Sodeyama T., Tanaka E., Nakano Y., Furuta S., Nishioka K., Purcell R.H., Alter H.J. Hepatitis C in hospital employees with needlestick injuries. Ann. Intern. Med. 1991, 115:367-369.
32. Metzger D.S., Koblin B., Turner C., Navaline H., Valenti F., Holte S., Gross M., Sheon A., Miller H., Cooley P., Seage G.R. Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am. J. Epidemiol. 2000, 152:99-106.
33. Miller C.L., Johnston C., Spittal P.M., Li K., Laliberte N., Montaner J.S., Schechter M.T. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002, 36:737-742.
34. Mitsui T., Iwano K., Masuko K., Yamazaki C., Okamoto H., Tsuda F., Tanaka T., Mishiro S. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992, 16:1109-1114.
35. Neaigus A., Gyarmathy V.A., Miller M., Frajzyngier V.M., Friedman S.R., Des Jarlais D.C. Transitions to injecting drug use among noninjecting heroin users: social network influence and individual susceptibility. J. Acquir. Immune Defic. Syndr. 2006, 41:493-503.
36. Ouellet L., Huo D., Bailey S.L. HIV risk practices among needle exchange users and nonusers in Chicago. J. Acquir. Immune Defic. Syndr. 2004, 37:1187-1196.
37. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 2006, 45:529-538.
38. Reyes J.C., Colon H.M., Robles R.R., Rios E., Matos T.D., Negron J., Marrero C.A., Calderon J.M., Shepard E. Prevalence and correlates of hepatitis C virus infection among street-recruited injection drug users in San Juan, Puerto Rico. J. Urban Health 2006, 83:1105-1113.
39. Rhodes T., Platt L., Maximova S., Koshkina E., Latishevskaya N., Hickman M., Renton A., Bobrova N., McDonald T., Parry J.V. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction 2006, 101:252-266.
40. Rockwell R., Des Jarlais D.C., Friedman S.R., Perlis T.E., Paone D. Geographic proximity, policy and utilization of syringe exchange programmes. AIDS Care 1999, 11:437-442.
41. Romanowski B., Preiksaitis J., Campbell P., Fenton J. Hepatitis C seroprevalence and risk behaviors in patients attending sexually transmitted disease clinics. Sex. Transm. Dis. 2003, 30:33-38.
42. Taylor A., Goldberg D., Hutchinson S., Cameron S., Gore S.M., McMenamin J., Green S., Pithie A., Fox R. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working?. J. Infect. Dis. 2000, 40:176-183.
43. Thomas D.L., Vlahov D., Solomon L., Cohn S., Taylor E., Garfein R., Nelson K.E. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995, 74:212-220.
44. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., Monterroso E.R., Garfein R.S. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am. J. Epidemiol. 2002, 155:645-653.
45. Thorpe L.E., Ouellet L.J., Levy J.R., Williams I.T., Monterroso E.R. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. J. Infect. Dis. 2000, 182:1588-1594.
46. van den Hoek J.A., van Haastrecht H.J., Goudsmit J., de Wolf F., Coutinho R.A. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J. Infect. Dis. 1990, 162:823-826.
47. Villano S.A., Vlahov D., Nelson K.E., Lyles C.M., Cohn S., Thomas D.L. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J. Clin. Microbiol. 1997, 35:3274-3277.
48. Wodak A., Cooney A. Effectiveness of sterile needle and syringe programmes. Int. J. Drug Policy 2005, 16S:S31-S44.
49. Wylie J.L., Shah L., Jolly A. Incorporating geographic settings into a social network analysis of injection drug use and bloodborne pathogen prevalence. Health Place 2007, 13:617-628.
50. Wylie J.L., Shah L., Jolly A.M. Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada. BMC Public Health 2006, 6:229.
51. Zarski J.P., Bohn B., Bastie A., Pawlotsky J.M., Baud M., Bost-Bezeaux F., Tran van Nhieu J., Seigneurin J.M., Buffet C., Dhumeaux D. Characteristics of patients with dual infection by hepatitis B and C viruses. J. Hepatol. 1998, 28:27-33.